Foundation Fighting Blindness and Usher 1F Collaborative to Launch Natural History Study
The project will help identify outcome measures for future clinical trials of potential USH1F therapies.
News provided by
Share this article
COLUMBIA, Md., April 29, 2021 /PRNewswire/
Foundation Fighting Blindness, the world s leading organization committed to finding treatments and cures for blinding retinal diseases, is partnering with the Usher 1F Collaborative, a family-founded nonprofit driving research for Usher syndrome type 1F (USH1F), to launch a natural history study, the Rate of Progression in
PCDH15-Related Retinal Degeneration in Usher Syndrome 1F (RUSH1F). Additional funding for the project will be provided by the Marjorie C. Adams Trust.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10
ProQR Therapeutics N.V.January 7, 2021 GMT
Top-line results expected H1 2022
Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal disorder that leads to blindness
LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced it has completed patient enrollment in its Phase 2/3